European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10332353" target="_blank" >RIV/00669806:_____/16:10332353 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/16:10332353

Result on the web

<a href="http://dx.doi.org/10.1016/j.eururo.2016.06.009" target="_blank" >http://dx.doi.org/10.1016/j.eururo.2016.06.009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.eururo.2016.06.009" target="_blank" >10.1016/j.eururo.2016.06.009</a>

Result language

angličtina

Original language name

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Original language description

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FJ - Surgery including transplantology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Urology

ISSN

0302-2838

e-ISSN

—

Volume of the periodical

70

Issue of the periodical within the volume

5

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

2

Pages from-to

705-706

UT code for WoS article

000385515600001

EID of the result in the Scopus database

2-s2.0-84977627563